Skip to main content

Table 1 Patient Demographics

From: “B in IT” - a community-based model for the management of hepatitis B patients in primary care clinics using a novel web-based clinical tool

Characteristic “B in IT” patients Control patients P values
Total Number 30 60  
 Female 19 (63.3%) 38 (63.3%) 1.000
 Male 11 (36.7%) 22 (36.7%) 1.000
Age (years) mean ± SD 55.6 ± 12.6 55.3 ± 11.6 0.985
 Female 53.8 ± 10.7 54.0 ± 10.4 0.867
 Male 58.6 ± 15.4 57.6 ± 13.4 0.889
Ethnicity
 Asian 24 (80%) 48 (80%) 1.000
 Sub-Saharan African 3 (10%) 6 (10%) 1.000
 European 2 (6.7%) 4 (6.7%) 1.000
 Pacific Islander 1 (3.3%) 2 (3.3%) 1.000
Preferred Language
 English 12 (40%) 30 (50%) 0.502
 Vietnamese 6 (20%) 14 (23.3%) 0.794
 Mandarin 4 (13.3%) 7 (11.7%) 1.000
 Hakka Timorese 3 (10%) 1 (1.7%) 0.106
 Cantonese 2 (6.7%) 4 (6.7%) 1.000
 Other 3 (10%) 4 (6.7%) 0.682
Liver Clinic Visits
  < 5 10 (33.3%) 11 (18.3%) 0.185
 5-10 8 (26.7%) 13 (21.7%) 0.791
  > 10 12 (40%) 36 (60%) 0.116
Breaks in care (> 1 year)
 N/A (seen < 1 year) 9 (30%) 4 (6.7%) 0.005a
 0 12 (40%) 47 (78.3%) 0.0005a
 1 7 (23.3%) 6 (10%) 0.115
 2 1 (3.3%) 3 (5%) 1.000
  > 2 1 (3.3%) 0 (0%) 0.333
HBeAg Status
 Negative 29 (96.7%) 57 (95%) 1.000
 Positive 1 (3.3%) 3 (5%) 1.000
Phase of disease
 1 – immune tolerance 0 (0%) 0 (0%) 1.000
 2 – immune clearance 1 (3.3%) 3 (5%) 1.000
 3 – immune control 23 (76.7%) 44 (73.3%) 0.802
 4 – immune escape 5 (16.7%) 9 (15%) 1.000
Cleared (HBsAb positive) 1 (3.3%) 4 (6.7%) 0.661
Cirrhosis 0 (0%) 0 (0%) 1.000
Treatment type
 Monitoring 24 (80%) – 20 with HCC screening 48 (80%) – 40 with HCC screening 1.000
 Antiviral therapy 6 (20%) – 5 with HCC screening 12 (20%) – 10 with HCC screening 1.000
  Entecavir 5 (16.7%) 10 (16.7%) 1.000
  Tenofovir 1 (3.3%) 2 (3.3%) 1.000
  1. SD standard deviation, N/A not applicable, HBeAg hepatitis B e antigen, HBsAb hepatitis B surface antibody; astatistically significant